KCM Investment Advisors LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,127 shares of the biopharmaceutical company’s stock after selling 35 shares during the period. KCM Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $554,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of REGN. Gabelli Funds LLC boosted its position in Regeneron Pharmaceuticals by 13.3% in the first quarter. Gabelli Funds LLC now owns 6,800 shares of the biopharmaceutical company’s stock valued at $2,635,000 after buying an additional 800 shares in the last quarter. Toronto Dominion Bank boosted its position in Regeneron Pharmaceuticals by 57.4% in the first quarter. Toronto Dominion Bank now owns 20,540 shares of the biopharmaceutical company’s stock valued at $7,958,000 after buying an additional 7,487 shares in the last quarter. NEXT Financial Group Inc boosted its position in Regeneron Pharmaceuticals by 2.3% in the first quarter. NEXT Financial Group Inc now owns 916 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 21 shares in the last quarter. Virginia Retirement Systems ET AL boosted its position in Regeneron Pharmaceuticals by 140.1% in the first quarter. Virginia Retirement Systems ET AL now owns 41,300 shares of the biopharmaceutical company’s stock valued at $16,004,000 after buying an additional 24,100 shares in the last quarter. Finally, CIBC World Markets Inc. boosted its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares in the last quarter. Hedge funds and other institutional investors own 67.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/regeneron-pharmaceuticals-inc-regn-shares-sold-by-kcm-investment-advisors-llc.html.

In related news, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $500.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $1,500,000. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Robert E. Landry sold 663 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total transaction of $330,571.80. Following the transaction, the senior vice president now directly owns 10,099 shares of the company’s stock, valued at $5,035,361.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 99,543 shares of company stock valued at $47,831,369. 10.40% of the stock is currently owned by corporate insiders.

A number of analysts have weighed in on the stock. Morgan Stanley restated an “equal weight” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. Canaccord Genuity set a $522.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 14th. Leerink Swann restated an “outperform” rating and issued a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 14th. Finally, Citigroup Inc. raised their target price on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $491.43.

Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.77% during midday trading on Friday, hitting $433.45. 1,002,422 shares of the stock traded hands. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55. The stock’s 50-day moving average price is $472.80 and its 200-day moving average price is $445.37. The stock has a market capitalization of $45.96 billion, a P/E ratio of 43.48 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the company posted $2.82 EPS. Regeneron Pharmaceuticals’s revenue was up 21.2% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.90 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.